Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes

References

• DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127–38.
   PubMed Web of Science ®Google Scholar
• Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Med. 2017;130:S4–S17.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2019. Diabetes Care. 2019;42:S90–S102.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41:2669–2701.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary. Endocr Pract. 2019;25:69–100.
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Kohl BA. Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. Mayo Clin Proc. 2010;85:S15–S26.
   PubMedGoogle Scholar
• Testa R, Bonfigli AR, Prattichizzo F, et al. The “Metabolic Memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients. 2017;9(5).
   Web of Science ®Google Scholar
• DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535–1540.
   PubMed Web of Science ®Google Scholar
• Fu AZ, Sheehan JJ. Treatment intensification for patients with type 2 diabetes and poor glycaemic control. Diabetes Obes Metab. 2016;18:892–898.
   PubMed Web of Science ®Google Scholar
• Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20:427–437.
   PubMed Web of Science ®Google Scholar
• Mahabaleshwarkar R, Gohs F, Mulder H, et al. Patient and provider factors affecting clinical inertia in patients with type 2 diabetes on metformin monotherapy. Clin Ther. 2017;39:1658–1670.
   PubMed Web of Science ®Google Scholar
• Brouwer ES, West SL, Kluckman M, et al. Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. Pharmacoepidemiol Drug Saf. 2012;21:920–928.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380:347–357.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–1529.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care. 2017;40:706–714.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385:2107–2117.
   PubMed Web of Science ®Google Scholar
• Kleinridders A, Ferris HA, Cai W, et al. Insulin action in brain regulates systemic metabolism and brain function. Diabetes. 2014;63:2232–2243.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–225.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes. 2013;62:3324–3328.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Gao HK, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6:e004007.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39.
   PubMed Web of Science ®Google Scholar
• Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety cardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11–23.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691–704.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical Companies of Johnson & Johnson. Phase 3 CREDENCE renal outcomes trial of INVOKANA® (canagliflozin) is being stopped early for positive efficacy findings. 2018 [cited 2019 Jan 3]. Available from: https://www.janssen.com/phase-3-credence-renal-outcomes-trial-invokanar-canagliflozin-being-stopped-early-positive-efficacy
   Google Scholar
• Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249–259.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:1845–1855.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Liontos A, Papakitsou I, et al. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019;131:82–88.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, DeMets DL, Inzucchi SE, et al. DAPA-HF–the dapagliflozin and prevention of adverse-outcomes in heart failure trial. Paper presented at: European Society of Cardiology–World Congress of Cardiology 2019; 2019 Aug 31–Sept 4; Paris, France.
   Google Scholar
• McMurray JJV, DeMets DL, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Sep 19. Epub ahead of print. DOI:10.1056/NEJMoa1911303
   Google Scholar
• Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923–1934.
   PubMed Web of Science ®Google Scholar
• Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract. 2018;4:477–482.
   PubMed Web of Science ®Google Scholar
• Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41:1801–1808.
   PubMed Web of Science ®Google Scholar
• van Baar MJB, van Ruiten CC, Muskiet MHA, et al. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41:1543–1556.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566–592.
   PubMed Web of Science ®Google Scholar
• Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci. 2015;9:92.
   PubMed Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–837.
   PubMed Web of Science ®Google Scholar
• Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med. 2017;129:686–697.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–851.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Thompson VP, Aguilar D, et al. Effects of once-weekly exenatide on clinical outcomes in patients with preexisting cardiovascular disease: a prespecified analysis from EXSCEL. Circulation. 2018;138:2576–2578.
   PubMed Web of Science ®Google Scholar
• Clegg LE, Penland RC, Boulton DW, et al. Effect of open-label SGLT2 inhibitor treatment when combined with exenatide on cardiovascular and renal outcomes in EXSCEL. Diabetes. 2019;68:6–LB.
   Google Scholar
• Gentilella R, Pechtner V, Corcos A, et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev. 2019;35:e3070.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes Obes Metab. 2019 Jul 30 Epub ahead of print. DOI:10.1111/dom.13847.
   Web of Science ®Google Scholar
• Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–113.
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788–1803.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab. 2017;43:S13–S19.
   Web of Science ®Google Scholar
• DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19:1353–1362.
   PubMed Web of Science ®Google Scholar
• Mazidi M, Karimi E, Rezaie P, et al. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications. 2017;31:1237–1242.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131–138.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes – 2019. Diabetes Care. 2019;42:S61–S70.
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Frias JP, Hardy E, et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care. 2018;41:2136–2146.
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D, Sasaki T, et al. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study. J Diabetes Invest. 2018;9:332–340.
   PubMed Web of Science ®Google Scholar
• Harashima SI, Inagaki N, Kondo K, et al. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week, open-label, phase IV study. Diabetes Obes Metab. 2018;20:1770–1775.
   PubMed Web of Science ®Google Scholar
• Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:370–381.
   PubMed Web of Science ®Google Scholar
• Curtis L, Humayan MA, Walker J, et al. Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control. Pract Diabetes. 2016 May 10 [cited 2019 Jan 18]. Available from: http://www.practicaldiabetes.com/article/addition-sglt2-inhibitor-glp-1-agonist-therapy-people-type-2-diabetes-suboptimal-glycaemic-control/
   Web of Science ®Google Scholar
• Saroka RM, Kane MP, Busch RS, et al. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. Endocr Pract. 2015;21:1315–1322.
   PubMed Web of Science ®Google Scholar
• Deol H, Lekkakou L, Viswanath AK, et al. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience. Endocrine. 2017;55:173–178.
   PubMed Web of Science ®Google Scholar
• Zhang N, Yang X, Zhu X, et al. Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: national health and nutrition examination survey (NHANES) 1999–2010. J Int Med Res. 2017;45:594–609.
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Frias JP, Guja C, et al. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab. 2018;20:1515–1519.
   PubMed Web of Science ®Google Scholar
• Jung CH, Mok JO. The effects of hypoglycemic agents on non-alcoholic fatty liver disease: focused on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. J Obes Metab Syndr. 2019;28:18–29.
   PubMed Web of Science ®Google Scholar
• Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40:1310–1319.
   PubMed Web of Science ®Google Scholar
• Sawada K, Karashima S, Kometani M, et al. Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes. Endocr J. 2018;65:461–467.
   PubMed Web of Science ®Google Scholar
• Consoli A, Formoso G, Baldassarre MPA, et al. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf. 2018;17:293–302.
   PubMed Web of Science ®Google Scholar
• Jabbour S, Guja C, Hardy E, et al. DURATION-8 Randomized controlled trial 104-week results—once weekly exenatide once weekly (ExQW) plus dapagliflozin (DAPA) vs. ExQW or DAPA alone. Diabetes. 2018 Jul;67(Supple1):104–LB.
   Google Scholar
• Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab. 2019;21:34–42.
   PubMed Web of Science ®Google Scholar
• Invokana® (canagliflozin) tablets, for oral use: US prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2018.
   Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
   PubMed Web of Science ®Google Scholar
• Steglatro™ (ertugliflozin) tablets, for oral use: US prescribing information. Whitehouse, NJ: Merck & Co., Inc.; 2018.
   Google Scholar
• Chang HY, Singh S, Mansour O, et al. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med. 2018;178:1190–1198.
   PubMed Web of Science ®Google Scholar
• Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab. 2018;20:1531–1534.
   PubMed Web of Science ®Google Scholar
• Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20:2585–2597.
   PubMed Web of Science ®Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–1693.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections 2015. [cited 2019 Jan 16]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM475487.pdf.
   Google Scholar
• Victoza® (liraglutide injection): US prescribing information. Princeton, NJ: Novo Nordisk A/S. revised 2017.
   Google Scholar
• Trulicity® (dulaglutide injection) for subcutaneous use: US prescribing information. Indianapolis, IN: Eli Lilly and Company. revised 2019.
   Google Scholar
• Tanzeum® (albiglutide injection), for subcutaneous use: US prescribing information. Wilmington, DE: GlaxoSmithKline LLC. revised 2019.
   Google Scholar
• Bydureon® (exenatide extended-release) for injectable suspension: US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP. revised 2019.
   Google Scholar
• Esposito K, Bellastella G, Giugliano D. When metformin fails in type 2 diabetes mellitus. Arch Intern Med. 2011;171:365–366.
   PubMedGoogle Scholar
• Ackermann RT, Wallia A, O’Brien MJ, et al. Correlates of second-line type 2 diabetes medication selection in the USA. BMJ Open Diabetes Res Care. 2017;5:e000421.
   PubMedGoogle Scholar
• Amaryl® (glimepiride) tablets: US prescribing information. Bridgewater, NJ: Sanofi-aventis U.S. LLC. revised 2013.
   Google Scholar
• Glynase® PresTab® (glyburide) tablets: US prescribing information. New York, NY: Pharmacia & Upjohn Co.; 2017.
   Google Scholar
• Glucotrol® (glipizide) tablets: US prescribing information. New York, NY: Pfizer; 2016.
   Google Scholar
• Polonsky WH, Jackson RA. What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22:147–150.
   Google Scholar
• Ozempic® (semaglutide injection): US prescribing information. Plainsboro, NJ: Novo Nordisk A/S; 2017.
   Google Scholar
• Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res. 2012;2012:672658.
   PubMedGoogle Scholar
• Charokopou M, Vioix H, Verheggen BG, et al. Economic assessment of delaying insulin treatment through the use of newer anti-diabetic agents, dapagliflozin (Forxiga®) and exenatide (Bydureon®), both as add-on to metformin; a cost-effectiveness analysis from a UK NHS perspective. Value Health. 2014;17:A344–A345.
   PubMed Web of Science ®Google Scholar